ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > How much will people pay to applaud?

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Aug 18, 2021 8:55am

97 Views

Post# 33722489

RE:How much will people pay to applaud?

STT, chances are the SP will Increase to high 20's once again and Drop within 1-2 Weeks.
If there is no Movement forward in regards to Revenue, there is no chance the SP will stay up.
0.75 might be possible by Years End if they bring in a New CEO.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property